Lars Lannfelt – Co-Founder & Board Member, BioArctic
Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this…
BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs.
Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.
Contact
Warfvinges väg 35, 112 51 Stockholm
Tel: 08-695 69 30
Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this…
BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for patients with neurodegenerative diseases, such as Alzheimer’s disease…
In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent…
Anette Steenberg, CEO of Medicon Valley Alliance, discusses how the Danish-Swedish cross-border innovation hub is positioning the region as a global leader in life sciences. The Alliance leverages regional strengths…
Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this…
PharmaBoardroom caught up with Niklas Hedberg at DIA Europe 2024 in Brussels to gauge what more needs to be done ahead of the implementation of European HTA regulation in January…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for…
Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Petter Hartman of the Medicon Valley Alliance, a non-profit membership organisation spanning the Danish-Swedish life science cluster Medicon Valley, introduces the progress of the Alliance from a networking body to…
In a wide-ranging interview, AbbVie’s Linn Mandahl discusses how the reorganisation of Scandinavian operations back in 2018 has put the company back on a growth trajectory in the region. Mandahl…
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
See our Cookie Privacy Policy Here
